Sydney Jennings

In a real-world study of patients with Crohn disease, upadacitinib achieved 52.1% clinical remission at 12 weeks and 42.7% endoscopic remission at 6 months, with no new safety concerns reported.

Your daily dose of the clinical news you may have missed.

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

Northstrive Biosciences received positive FDA feedback for its IND application for EL-22, a probiotic-based treatment for obesity.

Your daily dose of the clinical news you may have missed.

A quick look at the states ranking highest and lowest on metrics including influenza vaccination, tetanus vaccination, HPV vaccination, and more.

New data also demonstrated mixed sex disparities in elderly atopic dermatitis prevalence.

Your daily dose of the clinical news you may have missed.

A recent survey of US adults sheds light on public attitudes regarding RSV, influenza, COVID-19, MMR, and other key vaccines.

Novavax’s COVID-19 vaccine was linked to fewer and less severe side effects vs mRNA in a University of Utah study of health care workers.

Your daily dose of the clinical news you may have missed.

ACP 2025: Dr Kalager shares strategies for addressing patient beliefs, presenting risk data, and promoting shared decision-making in primary care settings.

ACP 2025: Collaborative care can help address the mental health crisis, but payment and EHR challenges remain. Matthew Press, MD, explains how primary care can overcome these barriers and why integration is essential.

Your daily dose of the clinical news you may have missed.

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

The CDC advisory committee also endorsed GSK's pentavalent meningococcal vaccine.

ACP 2025: Matthew Press, MD, shares actionable steps for primary care physicians to adopt a collaborative care model, including how to start small and partner with other practices.

Your daily dose of the clinical news you may have missed.

Review 10 new FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for UTIs, acute pain, and more.

ACP 2025: GLP-1 medications are advancing obesity care, but lifestyle changes and bariatric surgery remain key components. Laura Davisson, MD, discusses how to personalize treatment strategies.

Your daily dose of the clinical news you may have missed.

ACP 2025: Dr Press discusses how the Penn Integrated Care model equips primary care physicians to manage mental health conditions more effectively while reducing burnout.

Data from the EAGLE-1 study found gepotidacin to be noninferior to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhea.

Your daily dose of the clinical news you may have missed.

The FDA and Novo Nordisk are urging health care professionals to check semaglutide (Ozempic) injection 1 mg lot PAR0362 with serials starting 51746517.

ACP 2025: Lung cancer is rising among nonsmokers, especially women. Kim Sandler, MD, discusses future screening challenges, research insights, and the need to expand screening eligibility.

Your daily dose of the clinical news you may have missed.

ACP 2025: Discover how the collaborative care model supports mental health in primary care through team-based care, symptom tracking, and psychiatric consultation—boosting outcomes and reducing burden on clinicians.

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.